Maxim Group Reiterates “$5.00” Price Target for Soligenix (SNGX)
Soligenix (NASDAQ:SNGX) has been assigned a $5.00 price target by analysts at Maxim Group in a note issued to investors on Wednesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target indicates a potential upside of 108.33% from the stock’s previous close.
Separately, HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Soligenix in a report on Thursday, September 21st.
Soligenix (NASDAQ:SNGX) traded up $0.16 during trading hours on Wednesday, hitting $2.40. The company had a trading volume of 114,841 shares, compared to its average volume of 332,450. Soligenix has a 12-month low of $1.74 and a 12-month high of $5.08. The stock has a market capitalization of $19.56, a PE ratio of -2.38 and a beta of 2.17.
In other news, insider Spa Essetifin purchased 293,510 shares of the business’s stock in a transaction on Wednesday, November 29th. The stock was acquired at an average price of $2.12 per share, for a total transaction of $622,241.20. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 5.03% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Maxim Group Reiterates “$5.00” Price Target for Soligenix (SNGX)” was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/03/maxim-group-reiterates-5-00-price-target-for-soligenix-sngx.html.
Soligenix Company Profile
Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.